Drug resistance has been a major limitation to chemotherapy. There are many mechanisms that contribute to such resistance. In our study, we subcloned oridonin-sensitive and low sensitive L929 cells and both types of cells grew at almost the same growth rate. The acquired low sensitivity to oridonin-induced apoptosis was associated with Bcl-2 up-regulation and down-regulation of p53 phosphorylation. The p38 inhibitor SB203580 decreased Bcl-2 expression in the low sensitive L929 cells and made the cells more sensitive to oridonin. Moreover, a higher dose of oridonin promoted p53 phosphorylation, increased Bax expression and subsequently induced death of low sensitive L929 cells, however, it had no effect on Bcl-2 expression. The increased Bcl-2/Bax ratio in oridonin low sensitive L929 cells did not inhibit caspase-9 or -3 activation, but suppressed the cleavage of poly (ADP-ribose) polymerase (PARP), indicating the existence of caspase-9 or -3 independent PARP activation. These results indicated that in L929 cells, there was a relationship among the low sensitivity to oridonin, downregulation of p53 phosphorylation and Bcl-2 up-regulation.
The drug resistance of a tumor is a major problem in the treatment of cancer, and is the result of re-growth of a tumor that is no longer sensitive to the original drug. A number of mechanisms may contribute to cellular drug resistance, such as reduced intracellular drug concentrations, rapid inactivation of the drug by induction of certain enzyme systems and increased rate of DNA repair. 1) Dysregulation of apoptosis, a genetically controlled form of cell death, may also be important for drug resistance because the mechanism by which most chemotherapeutic agents induced cell death appeared to be apoptosis. 2) Identification of the gene related to apoptosis and gene products and investigation of the mechanisms of the apoptotic regulation have laid a foundation for the discovery of new drugs. It is well known that among the proteins involved in the regulation of cell death, the p53 and p53-regulated proteins, the caspase family, the mitochondrial Bcl-2 family and the mitogen-activated protein kinase (MAPK) family function as the key factors in inhibiting or promoting apoptosis. [3] [4] [5] [6] Herbal medicine, Donglingcao (Rabdosia rubescens), has been traditionally used in China. Diterpenoids are the major constituent of R. rubescens and oridonin ( Fig. 1) is a diterpenoid isolated from R. rubeseens, which has been reported to have various pharmacological and physiological effects of anti-inflammation, anti-bacteria and anti-tumor. 7, 8) In our previous study, we had reported that oridonin had apoptosis-inducing activities in murine L929 fibrosarcoma cells through a caspase-independent but mitochondria-and MAPK-dependent pathway and that caspase inhibitor augmented the cell death. 9) In the process of investigating the cytotoxic effect of oridonin on L929 cells, we found that part of these cells had low sensitivity to oridonin, although the mechanism is still unclear. The focus of our current study was to investigate the mechanism that regulate apoptosis and induce low drug sensitivity, and for this purpose both oridonin-sensitive and low sensitive L929 cells were subcloned.
In this study, we for the first time demonstrated that the low sensitivity to oridonin in L929 cells was associated with suppression of drug-induced apoptosis, which was the result of up-regulation of Bcl-2 expression, down-regulation of p53 phosphorylation and inhibition of PARP fragmentation. The p38 inhibitor SB203580 decreased Bcl-2 expression and increased oridonin-induced cell death in the low sensitive L929 cells. Moreover, a high dose of oridonin promoted p53 phosphorylation and increased Bax expression in the same low sensitive cells.
MATERIALS AND METHODS

Chemical Material
Oridonin was obtained from the Beijing Institute of Biological Products (Beijing China). The structure of oridonin was assigned by comparing the chemical and spectral data ( 1 H-,
13
C-NMR) with those reported in the literature. The purity of the oridonin was measured by HPLC and determined to be 99.2% and oridonin was dissolved in the medium.
Biological Material 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), ribonuclease (RNase), proteinase K, propidium iodide (PI) and Hoechst 33258 were purchased from Sigma Chemical (St. Louis, MO, U.S.A.). Caspase-9 inhibitor (z-LEHD-fmk) and caspase-3 inhibitor (z-DEVD-fmk) were purchased from Enzyme Systems (Sacramento, CA, U.S.A.). ERK inhibitor (PD98059), p38 inhibitor (SB203580) and JNK inhibitor (SP600125) were obtained from Calbiochem (CA, U.S.A.). Polyclonal antibodies against p38, phospho-p38, PARP, b-actin, and horseradish peroxidase-conjugated secondary antibodies (goat-anti-rabbit and goat-anti-mouse) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.A.). Antibodies against p53, Bcl-2 and Bax were obtained from Oncogene Research Products (Boston, MA, U.S.A.). Caspase-9 colorimetric activity assay kit was purchased from Chemicon International (CA, U.S.A.) and caspase-3 apoptosis kit was from Santa Cruz Biotechnology.
Cell Culture The oridonin sensitive and oridonin resistant subclonal cells were derived from the murine fibrosarcoma L929 cells purchased from the American Type Culture Collection (#CRL-2148, ATCC, Manassas, VA, U.S.A.). The cells were cultured in RPMI-1640 medium (GIBCO, NY, U.S.A.) supplemented with 10% FBS (Shengma Yuanheng, Beijing, China), 100 mg/l streptomycin, 100 IU/ml penicillin, and 0.03% L-glutamine and maintained at 37°C with 5% CO 2 in a humidified atmosphere.
Subclone of L929 Cells L929 cells in RPMI-1640 supplemented with 10% fetal bovine serum were seeded into 96-well plates at the density of 3ϫ10 3 cells/l in order to form single-cell clone in one well. Thirty-six single-cell clones were obtained using a microscope and cultured in RPMI-1640 medium containing 10% FBS for screening sensitive cells. Cytotoxic effects of oridonin on those single-cell clones were detected and oridonin sensitive cells were obtained. The original L929 cells were treated with 33.6 mM oridonin (IC 50 of oridonin on the original L929 cells) and the live cells were further cultured in RPMI-1640 medium containing 10% FBS. The live cells were repeatedly treated 3 times with 33.6 mM oridonin and oridonin low sensitive L929 cells were also obtained.
Cell Cycle Distribution Assay L929 cells (1ϫ10 6 ) were incubated with 2.5 mM thymidine (cell cycle blocker from G1 to S phase) for 18 h, and collected by centrifugation at 100ϫg for 5 min. The cells were suspended in RPMI-1640 medium supplemented with 10% fetal bovine serum and cultured for 15 h. They were treated with 2.5 mM thymidine for 15 h again, centrifuged at 100ϫg for 5 min, washed by phosphorylated buffer salined (PBS), then further cultured in RPMI-1640 containing 10% fetal bovine serum and collected at 0, 8, 16 and 24 h. The cells were washed by PBS and stained with PI followed by flow cytometric analysis.
Cytotoxity Assay L929 cells were incubated at 1ϫ10 Flow Cytometric Analysis L929 cells, both adherent and floating, were pelleted and washed with PBS. The cells were fixed in 75% ethanol at 4°C overnight. After washing twice with PBS, the cells were stained with propidium iodine (1.0 ml, 50 mg/l), RNase A (1 g/l) and 0.1% Triton X-100 in sodium citrate (3.8 mM), followed by incubation on ice in the dark for 30 min. Samples were analyzed by a flow cytometer (Becton Dickinson FACScan, Franklin Lakes, CA, U.S.A.) with Cell Quest software, which was used to determine the percentage of cells in different phases of the cell cycle.
Nuclear Damage Observed by Hoechst 33258 Staining Apoptotic nuclear morphology was assessed using Hoechst 33258. Cells were fixed with 3.7% paraformaldelyde for 30 min at room temperature, and then washed and stained with 167 mM Hoechst 33258 at 37°C for 30 min. Cells were again washed and resuspended in PBS for morphological observation using a fluorescence microscope (Leica, Wetzlar, Germany).
DNA Fragmentation Assay L929 Cells (1ϫ10 6 ) were collected by centrifugation at 150ϫg for 5 min, and washed with PBS. The cells were pelleted and suspended in 10 mM Tris (pH 7.4), 10 mM EDTA (pH 8.0) and 0.5% Triton X-100, then kept at 4°C for 10 min. The supernatant was incubated with 20 mg/ml RNase A (2 ml) and 20 mg/ml proteinase K (2 ml) at 37°C for 1 h, then kept in 0.5 M NaCl (20 ml) and isopropanal (120 ml) at Ϫ20°C overnight, and centrifuged at 15000ϫg for 15 min. DNA was dissolved in TE buffer [10 mM Tris (pH 7.4), 10 mM EDTA (pH 8.0)], subjected to 2% agarose gel electrophoresis at 50 V for 40 min and stained with ethidium bromide.
Caspase Activity Assay L929 cells were cultured at 1ϫ10 6 cells and treated with or without oridonin for different time periods. The enzymatic reaction for caspase-3 activity was carried out with caspase-3 substrate (DEVD-AFC) according to the manufacturer's instructions. The activity of caspase-9 was measured by a caspase-9 colorimetric activity assay kit.
Westernblot Analysis L929 cells were treated with oridonin for different time periods. Both adherent and floating cells were collected, and then Westernblot analysis was carried out as previously described with some modification. Briefly, the cell pellets were resuspended in lysis buffer consisting of Hepes 50 mmol/l pH 7.4, Triton-X 100 1%, sodium orthovanadate 2 mmol/l, sodium fluoride 100 mmol/l, edetic acid 1 mmol/l, PMSF 1 mmol/l, aprotinin (Sigma, MO, U.S.A.) 10 mg/l and leupeptin (Sigma) 10 mg/l and lysed at 4°C for 60 min. After 13000ϫg centrifugation for 15 min, the protein content of the supernatant was determined by a protein assay reagent (Bio-Rad U.S.A.). The protein lysates were separated by electrophoresis in 12% SDS polyacrylamide gel and blotted onto a nitrocellulose membrane. Proteins were detected using polyclonal antibody and visualized using anti-rabbit IgG conjugated with peroxidase (HRP) and 3,3-diaminobenzidine tetrahydrochloride (DAB) as the HRP substrate.
Statistical Analysis of the Data The data are expressed as meansϮS.D. Statistical comparisons were made by Student's t-test. pϽ0.05 was considered significant.
RESULTS
Cell Cycle Distribution of the Two Types of L929 Cells
To examine whether the two types of L929 cells have a similar cell growth cycle, flow cytometric analysis was applied. When the L929 cells were treated with 2.5 mM thymidine (an agent that blocks cell cycle transition from G1 to S phase) for indicated time periods, the cell cycle was effectively blocked at G1 phase; then, these cells were further cultured in RPMI-1640 containing 10% fetal bovine serum and collected at 0, 8, 16 and 24 h. The DNA contents were detected by fluorescence flow cytometry ( Table 1 ). The results showed that the two types of L929 cells grew at almost the same growth rate.
Cytotoxic Effects of Oridonin on Two Types of L929 Cells
The cytotoxic effects of oridonin on the two types of L929 cells were detected by culturing the cells with 2-12 mM oridonin for 24 h; we found that oridonin induced sensitive L929 cell death in a dose-dependent manner with an IC 50 value of 9.1 mM, but those doses of oridonin did not kill most of the low sensitive cells (Fig. 2A) . Higher doses of oridonin, 50-100 mM, however, exerted potent cytotoxic effects on the low sensitive cells with an IC 50 value of 81.2 mM (Fig.  2B) .
Atypical Apoptosis in the Two Types of L929 Cells Induced by Oridonin To investigate whether oridonin-induced cell death in the two types of L929 cells was caused by apoptosis, changes in DNA content during treatment with different doses of oridonin were monitored. The results showed that the apoptotic sub-G1 peaks were observed when the two types of cells were cultured with 9.1 and 81.2 mM oridonin, respectively, for 12 h (Figs. 3B, D) . To further confirm this, we also observed the morphologic changes by Hoechst 33258 staining. In the control group, nuclei of L929 cells were round and homogeneously stained (Figs. 3E, G) , however, oridonin-treated sensitive and low sensitive L929 cells showed granular apoptotic bodies (Figs. 3F, H) . Nucleosomal DNA fragmentation is another hallmark of typical apoptosis. 10) However, in our study, DNA ladders were not observed in the two types of cells treated with oridonin (data not shown).
Up-Regulation of Bcl-2 and Down-Regulation of Bax in Oridonin Low Sensitive L929 Cells
It is reported that the Bcl-2 family proteins play important roles in either inhibition or promotion of apoptotic cell death.
11) The higher expression of Bcl-2 in human melanoma and other tumors has been correlated with resistance to chemotherapy. 12) We also examined the expression of Bcl-2 family proteins, Bcl-2 and Bax, in the two types of cells treated with oridonin by Westernblot analysis. The results showed that when the two types of the cells were treated with 9.1 mM oridonin for different time periods, the expression of Bax protein was up-regulated in the sensitive cells and that of Bcl-2 was down-regulated, however, in the low sensitive cells, Bax and Bcl-2 expressions did not change. The elevated Bcl-2/Bax ratio might be characteristic of the low sensitivities to oridonin (Fig. 4) .
p38 Was Responsible for Bcl-2 Up-Regulation in Oridonin Low Sensitive L929 Cells MAPK signaling pathways have been shown to be implicated in cell growth and cell death. 6) For the examination of MAPK participation in the oridonin low sensitivities, specific inhibitors for p38 (SB203580), JNK (SP600125) and ERK (PD98059) were employed in the two types of cells. After incubation with 9.1 mM oridonin for 12 h, 5 mM SB 203580 or 5 mM SP600125 had almost no effect on the sensitive cell death while 5 mM PD98059 partially inhibited the cell death (Fig. 5A ). In the low sensitive cell cases, 5 mM SP600125 or 5 mM PD98059 also did not influence oridonin-induced cell death, however, 5 mM SB203580 increased it from 7.7% (cultured with 9.1 mM oridonin alone) to 37.5% (Fig. 5B) . These results showed that p38 signal pathways contributed to the oridonin low sensitivity in L929 cells. 2070 Vol. 28, No. 11
Fig. 2. Cytotoxic Effects of Oridonin on the Two Types of L929 Cells
The sensitive (Sen.) and low sensitive cells (L. sen.) were treated with 2-12 mM oridonin (A) and the latter were further treated with 50-100 mM oridonin (B) for 24 h. Cell death rate was measured by crystal violet assay. nϭ3, meanϮS.D. After treatment with 2.5 mM thymidine for the indicated time periods, the two types of L929 cells were further cultured in RPMI-1640 (containing 10% fetal bovine serum) and harvested at 0, 8, 16 and 24 h. The cells were washed by PBS and stained with PI followed by flow cytometric analysis. nϭ3, meanϮS.D.
Vega et al. reported that treatment of 2F7 cells with the p38 inhibitor SB203580 inhibited the constitutive p38 MAPK activity and resulted in inhibition of STAT3 activity and Bcl-2 expression, consequently sensitizing the drug-induced apoptosis. 13) In view of these reports, we examined the effects of p38 on the Bcl-2 expression by Westernblot analysis, and the result indicated that treatment with 5 mM SB203580 at 12 h decreased Bcl-2 expression in the oridonin low sensitive cells (Fig. 6A) . A higher dose of 81.2 mM oridonin did not alter the p38, p38 phosphorylation or Bcl-2 expression, but 5 mM SB203580 also decreased Bcl-2 expression (Fig. 6B) . These results demonstrated that p38 was involved in L929 cell low sensitivity to oridonin through upregulation of Bcl-2 expression in an oridonin dose-independent manner.
Contribution of p53 to the Low Sensitivity to Oridonin p53 plays an important role in induction cell cycle arrest and Flow cytometric analysis of cell cycle after the sensitive cells were treated with 9.1 mM oridonin, and low sensitive cells with 81.2 mM oridonin for 12 h. Morphological changes of nuclei were observed with Hoechst 33258 staining after the cells were cultured with oridonin for 18 h (ϫ200 magnification E, F, G, H; Sen., oridonin sensitive cell; L. sen., oridonin low sensitive cell; Or., oridonin).
Fig. 4. Westernblot Analysis of Bcl-2 and Bax Protein Expression in the Two Types of L929 Cells Treated with Oridonin
The oridonin sensitive and oridonin low sensitive cells were treated with 9.1 mM oridonin for different time periods. Cell lysates were separated by 12% SDS-PAGE electrophoresis, and the protein expression was detected by Westernblot analysis. Sen., oridonin sensitive cell; L. sen., oridonin low sensitive cell.
Fig. 5. Effects of MAPK Inhibitors on the Two L929 Cell Types
The oridonin sensitive (A: Sen) and the oridonin low sensitive cells (L. sen) were treated with 9.1 mM oridonin and MAPK inhibitors including 5 mM SP600125 (JNK),apoptosis and it has been reported that melanoma cell lines expressing wild type p53 exhibit a higher response to anticancer agents than melanoma with mutant p53. 14) Westernblot analysis was carried out to compare p53 expression in the two types of L929 cells treated with 9.1 mM oridonin. The p53 phosphorylation increased in the oridonin sensitive L929 cells, however, in the oridonin low sensitive cells, p53 phosphorylation was at low levels ( Fig. 7A) .
Wild type p53 promotes cell cycle arrest and apoptosis in response to DNA damage most likely by regulation of target genes Bcl-2 and Bax. 15, 16) After the low sensitive cells were treated with a high dose of 81.2 mM oridonin for 12 h, p53 phosphorylation and Bax expression increased, but Bcl-2 expression did not change, compared with 9.1 mM oridonintreated low sensitive cells (Fig. 7B) . These results suggested that a low expression of p53 phosphorylation might result in Bax expression at low levels and that this, in part, contributed to the low sensitivity to oridonin.
Up-Regulation of Bcl-2 Expression and Down-Regulation of Bax Expression Suppressed PARP Cleavage, But Did Not Inhibit Caspase Activation in the Oridonin Low Sensitive L929 Cells In mitochondria, when apoptosis occurs the cytochrome c is released into cytoplasm, and then cytochrome c, Apaf-1 and procaspase-9 form a complex. Activated caspase-9 cleaves caspase-3 proenzyme. 17) Poly (ADP-ribose) polymerase (PARP) is the substrate of caspase-3, and is cleaved to an 85-kDa fragment during apoptosis. 18) In our study, we used fluorometric assay to measure caspase-9 and -3 activities after treatment with 9.1 mM oridonin in the two types of L929 cells for different time periods. The results showed that caspase-9 or -3 activation was not suppressed in the oridonin low sensitive cells, but changed in almost the same degree to the oridonin sensitive cells (Fig. 8A) . In order to further confirm this result, the two types of cells were pretreated with caspase-9 inhibitor z-LEHD-fmk, and caspase-3 inhibitor z-DEVD-fmk, and then cultured with 9.1 mM oridonin for 15 h. z-LEHD-fmk and z-DEVD-fmk made the two types of cells even more sensitive to 9.1 mM oridonin. z-LEHD-fmk augmented the cell death by almost 12%, and z-DEVD-fmk increased the cell death by almost 22% in both cell types (Fig. 8B) , indicating that caspase-9 and -3 played protective roles in both cells, but did not mediate the oridonin-induced apoptosis.
To examine whether Bcl-2 up-regulation and Bax downregulation affected downstream PARP cleavage in the oridonin low sensitive L929 cells, Westernblot analysis was carried out to detect PARP fragmentation. After treatment with 9.1 mM oridonin for different time periods in the oridonin sensitive cells PARP was cleaved to an 85 kDa fragment (Fig.  9A) . However, in oridonin low sensitive cells, PARP was not cleaved, but p38 inhibitor SB203580 and a high dose of 81.2 mM oridonin promoted PARP fragmentation (Fig. 9B) . PARP inhibitor DPQ 20 mM partially inhibited the cell death in the oridonin sensitive and low sensitive L929 cells treated, respectively, with 9.1 or 81.2 mM oridonin (Fig. 9C) . It is reported that apoptosis-inducing factor (AIF) is confined to the mitochondrial intermembrane space. When apoptosis occurred AIF from the mitochondria translocated to the cytoplasm and nucleus and resulted in apoptosis in a caspase-independent manner. 19) Westernblot analysis performed to examine AIF expression in the oridonin sensitive and low sensitive L929 cells showed that in the 9.1 mM oridonin-treated sensitive cells, AIF significantly increased at 6 h, but in oridonin low sensitive cells, AIF was low but p38 inhibitor SB203580 or 81.2 mM oridonin promoted this expression (Fig. 10) . These results demonstrated that although in oridonin-treated L929 cells, caspase-9 and -3 protected against 2072 Vol. 28, No. 11 The oridonin sensitive and the oridonin low sensitive cells were treated with 9.1 mM or 81.2 mM oridonin for different time periods. Cell lysates were separated by 12% SDS-PAGE electrophoresis, and the protein expression was detected by Westernblot analysis. Or, oridonin; Sen., oridonin sensitive cell; L. sen., oridonin low sensitive cell.
Fig. 7. Effects of Different Doses of Oridonin on the p53 and Bax Expression in the Low Sensitive L929 Cells
The oridonin sensitive cells were treated with 9.1 mM and the oridonin low sensitive cells were with 9.1 mM or 81.2 mM oridonin for different time periods. Cell lysates were separated by 12% SDS-PAGE electrophoresis, and the protein expression was detected by Westernblot analysis. Or, oridonin; Sen., oridonin sensitive cell; L. sen., oridonin low sensitive cell.
the cell death, the suppression of PARP cleavage in oridonin low sensitive cells was still the result of a high ratio of upstream Bcl-2/Bax. PARP fragmentation and AIF expression were observed in 9.1 mM oridonin-treated sensitive cells and in a high dose of 81.2 mM oridonin-treated low sensitive L929 cells, therefore AIF might be responsible for PARP cleavage in a caspase-independent manner.
DISCUSSION
Resistance to chemotherapy or radiotherapy is a major obstacle for the treatment of malignant tumors that are surgically incurable because of their diffusely infiltrative nature. In addition to the conventional drug resistance mechanisms including drug intra/extracellular transport, mutation of the epidermal growth factor receptor (EGFR), secretion of antiapoptotic factor and DNA repair (1), suppression of apoptosis is another means of acquiring drug resistance and could be mediated by specific genetic alterations in tumor cells, such as inactivating mutations of p53 and/or overexpression of Bcl-2. 12, 14) In our study, subcloned oridonin-sensitive and low sensitive L929 cells were employed. The two types of L929 cells grew at almost the same growth rate and oridonin caused apoptosis in both.
Bcl-2 family members are characterized by containing at least one of four Bcl-2 homology domains (BH1-BH4), and play important roles in regulating apoptosis.
11) Bcl-2 seems to influence response to chemotherapy by inhibiting apopto- The two types of cells were treated with 9.1 mM oridonin for 15 h and caspase-9 and -3 activities were assayed (A). And in the presence of z-LEHD-fmk 5 mM (caspase-9) or z-DEVD-fmk 5 mM (caspase-3), cell death rate was measured by MTT assay. nϭ3, meanϮS.D., * pϽ0.05 and * * pϽ0.01. Sen., oridonin sensitive cell; L. sen., oridonin low sensitive cell.
Fig. 9. PARP Cleavage Was Inhibited in the Oridonin Low Sensitive L929 Cells
The oridonin sensitive cells were treated with 9.1 mM (A) and the oridonin low sensitive cells were with 9.1 mM or 81.2 mM oridonin (B, C) for different time periods and PARP inhibitor DPQ was added to cell in C. Cell lysates were separated by 12% SDS-PAGE electrophoresis and the protein expression was detected by Westernblot analysis (A, B) and cell death rate was measured by crystal violet assay (C). nϭ3, meanϮS.D., * * pϽ0.01. Or, oridonin; Sen., oridonin sensitive cell; L. sen., oridonin low sensitive cell. The oridonin sensitive cells were treated with 9.1 mM (A) and the oridonin low sensitive cells with 9.1 mM or 81.2 mM oridonin (B) for different time periods. Cell lysates were separated by 12% SDS-PAGE electrophoresis, and the protein expression was detected by Westernblot analysis. Or, oridonin; Sen., oridonin sensitive cell; L. sen., oridonin low sensitive cell. sis induced by many cytostatic drugs including alkylating agents, topoisomerase inhibitors and antimetabolities. 12) A recent study has shown that the simultaneous down-regulation of Bcl-2 expression and induction of apoptosis by antisense oligonucleotides in melanoma cells of different clinical stages might provide an additional clinical benefit. 20) In our experiments the results showed that Bcl-2 expressed at high levels in oridonin low sensitive L929 cells compared with the sensitive ones. It has been reported that treatment of 2F7 and 10C9 B Non-Hodgkin's lymphoma (NHL) with the p38 inhibitor SB203580 sensitized the cell lines to various chemotherapeutic drugs by down-regulation of Bcl-2 expression through inhibition of STAT3 transcriptional activity. 13) Endogenous nitric oxide down-regulates the Bcl-2 expression of eosinophils through mitogen-activated protein kinase p38 or ERK pathways in bronchial asthma.
21) The present study showed that p38 inhibitor SB203580 obviously inhibited Bcl-2 expression and augmented low sensitive L929 cell death at the dose of 9.1 mM oridonin indicating that p38 was involved in L929 cell low sensitivity to oridonin through up-regulation of Bcl-2 expression. Whether p38 regulated Bcl-2 expression through STAT3 pathways remains to be investigated. Ras gene mutation is very common in malignant tumor. 22 ) Ras proteins, upstream of p38, are regulators of multiple signal pathways that control cell growth and apoptosis. Ras oncogene is also involved in drug resistance, and the assumed mechanism is an up-regulation of Bcl-2 expression.
23) According to this, Ras gene might participate in L929 cells low sensitivity to oridonin and this also remains to be elucidated.
Bax, a proapoptotic protein, functions to promote apoptosis through suppressing antiapoptotic proteins Bcl-2 and Bcl-X L .
11) Raisova et al. reported that a low Bax/Bcl-2 ratio might be characteristic for drug-resistant melanoma cells. 24) Bax expression is regulated by p53, and wild p53 mediates cell cycle arrest and apoptosis in response to DNA damage, and p53 mutation is associated with drug resistance in malignant tumor. 15, 16) Our study showed that in oridonin low sensitive L929 cells, Bax and p53 phosphorylation expressed low and these could be reversed by high dose of 81.2 mM oridonin. Based on those results, we assumed that higher doses of oridonin might cause more serious DNA damage and this initiated multiple p53 activation, consequently increasing Bax expression.
Bax/Bcl-2 acts in mitochondria to cause the cytochrome c release into cytoplasm, and then cytochrome c, Apaf-1 and procaspase-9 form a complex which leads to caspase-9 activation; subsequently, activated caspase-9 cleaves caspase-3 proenzyme. PARP is a nuclear enzyme that responds to DNA damage, facilitates DNA repair and contributes to cell survival. It is cleaved to an 85-kDa fragment by caspase-3 when apoptosis occurred. 17, 18) In this study, caspase-9 and -3 did not execute apoptosis, but protected L929 cells against death, and their protease activities were not suppressed by the high ratio of Bcl-2/Bax in oridonin low sensitive cells. However, in the oridonin low sensitive cells, PARP degradation was inhibited in comparison with the sensitive cells, and p38 inhibitor SB203580 and a high dose of 81.2 mM oridonin promoted PARP fragmentation indicating that the suppression of PARP cleavage was still the result of Bcl-2 overexpression and the reduction of Bax expression.
In summary, we demonstrated that the L929 cells low sensitivity to oridonin was correlated with inhibition of drug-induced apoptosis, which was mediated by increased expression of Bcl-2 and decreased p53 phosphorylation which might result in down-regulation of Bax expression. The high ratio of Bcl-2/Bax was responsible for suppression of PARP fragmentation and subsequent cell survival. In the low sensitive L929 cells, p38 phosphorylated at high levels, and p38 inhibitor SB203580 partially suppressed the expression of Bcl-2 and augmented the cell death induced by oridonin.
